FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robbert Kauffmann

Research Profile

Living Beings

HIV-1

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

CD4-Positive T-Lymphocytes

Physiology

Immunologic Memory

Co-author Network

Publications

TOP 3
Katalin Pogány; Irene G M van Valkengoed; Irene G Vanvalkengoed; Jan M Prins; Pythia T Nieuwkerk; Ineke van der Ende; Robbert H Kauffmann; Frank P Kroon; Annelies Verbon; Marianne F Nievaard; Joep M A Lange; Kees Brinkman
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Charles J L la Porte; Emile F Schippers; Marchina E Van Der Ende; Peter P Koopmans; Willem L Blok; Robbert H Kauffmann; Frank P Kroon; David Burger
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
M G J de Boer; Frank P Kroon; Robbert H Kauffmann; Reinout Vriesendorp; Koos H Zwinderman; Jaap T van Dissel
Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robbert Kauffmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Katalin Pogány; Irene G M van Valkengoed; Irene G Vanvalkengoed; Jan M Prins; Pythia T Nieuwkerk; Ineke van der Ende; Robbert H Kauffmann; Frank P Kroon; Annelies Verbon; Marianne F Nievaard; Joep M A Lange; Kees Brinkman
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Journal of acquired immune deficiency syndromes (1999) 2007;44(4):395-400.
2005: Charles J L la Porte; Emile F Schippers; Marchina E Van Der Ende; Peter P Koopmans; Willem L Blok; Robbert H Kauffmann; Frank P Kroon; David Burger
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
AIDS (London, England) 2005;19(10):1105-7.
2003: M G J de Boer; Frank P Kroon; Robbert H Kauffmann; Reinout Vriesendorp; Koos H Zwinderman; Jaap T van Dissel
Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
The Netherlands journal of medicine 2003;61(12):408-12.
2001: Pythia T Nieuwkerk; Mirjam A G Sprangers; David Burger; Richard Hoetelmans; Patricia W H Hugen; Sven A Danner; Marchina E Van Der Ende; M M E Schneider; G Schrey; Pieter L Meenhorst; Herman Sprenger; Robbert H Kauffmann; Marielle Jambroes; Margaret A Chesney; Frank de Wolf; Joep M A Lange
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Archives of internal medicine 2001;161(16):1962-8.
2000: Kees Brinkman; Saskia M E Vrouenraets; Robbert H Kauffmann; Hugo M Weigel; J Frissen
Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis.
AIDS (London, England) 2000;14(17):2801-2.
1999: Daan W Notermans; Nadine Pakker; Dörte Hamann; NA Foudraine; Robbert H Kauffmann; Pieter L Meenhorst; Jaap Goudsmit; Marijke Th L Roos; P T A Schellekens; Frank Miedema; Sven A Danner
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
The Journal of infectious diseases 1999;180(4):1050-6.
1999: Nadine Pakker; E D Kroon; Marijke Th L Roos; Sigrid A Otto; D Hall; Ferdinand W N M Wit; Dörte Hamann; Marchina E Van Der Ende; Frans A Claessen; Robbert H Kauffmann; Peter P Koopmans; Frank P Kroon; C H ten Napel; Herman Sprenger; Hugo M Weigel; Julio S G Montaner; Joep M A Lange; Peter Reiss; P T A Schellekens; Frank Miedema
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
AIDS (London, England) 1999;13(2):203-12.
1998: Daan W Notermans; Suzanne Jurriaans; Frank de Wolf; NA Foudraine; JJ de Jong; W Cavert; CM Schuwirth; Robbert H Kauffmann; Pieter L Meenhorst; H McDade; C Goodwin; J M Leonard; Jaap Goudsmit; Sven A Danner
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
AIDS (London, England) 1998;12(2):167-73.
1997: AC Leenders; Peter Reiss; P Portegies; K Clezy; Wim C J Hop; Jennifer Hoy; Jan C C Borleffs; T Allworth; Robbert H Kauffmann; P Jones; Frank P Kroon; Henri A Verbrugh; Siem de Marie
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
AIDS (London, England) 1997;11(12):1463-71.
1997: Menno D De Jong; STEFANO VELLA; Andrew Carr; Charles A B Boucher; A Imrie; Martyn French; Jennifer Hoy; S Sorice; S Pauluzzi; F Chiodo; Gerrit Jan Weverling; Marchina E Van Der Ende; P J Frissen; Hugo M Weigel; Robbert H Kauffmann; Joep M A Lange; R Yoon; M Moroni; E Hoenderdos; G Leitz; David A Cooper; D Hall; Peter Reiss
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1994: Menno D De Jong; M Loewenthal; Charles A B Boucher; I van der Ende; D Hall; Pauline Schipper; A Imrie; Hugo M Weigel; Robbert H Kauffmann; R Koster
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
The Journal of infectious diseases 1994;169(6):1346-50.
1994: P H J Frissen; Marchina E Van Der Ende; C H ten Napel; Hugo M Weigel; G S Schreij; Robbert H Kauffmann; Peter P Koopmans; A I Hoepelman; J B de Boer; Gerrit Jan Weverling
Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1994;169(6):1351-5.